Reacción a "New migraine drugs less effective than triptans, says meta-analysis"

The study is of good quality. A considerable amount of data is analysed and the analysis has been conducted by well-known international experts in the diagnosis and treatment of migraine.

This analysis is in line with previously published analyses showing that triptans continue to be more effective than newer marketed drugs. However, some patients do not tolerate or have contraindications to the use of triptans, making alternative treatments such as rimegepant or lasmiditan essential. Furthermore, there is some evidence that frequent use of some of the drugs analysed, such as rimegepant or ubrogepant, is not associated with an increased risk of headache due to overuse of medication. In the case of rimegepant, the drug even has a preventive effect in reducing the number of headache days. This is a great advantage for gepants in patients who require frequent use of analgesics.

[Regarding possible limitations] This is a quality meta-analysis that attempts to compare the efficacy of different drugs. However, there is no direct comparative study of the drugs against each other, which would be the ideal way to know whether triptans are truly superior to the new drugs.